Screening of potential inhibitors of COVID-19 with repurposing approach via molecular docking

Article (Accepted Version)

Alizadehmohajer, Negin, Behmardi, Abtin, Najafgholian, Simin, Moradi, Shabnam, Mohammadi, Forogh, Nedaeminia, Reza, Haghjooy Javanmard, Shaghayegh, Sohrabi, Eshan, Salehi, Rasoul, Ferns, Gordon A, Emami Nejad, Asieh and Manian, Mostafa (2022) Screening of potential inhibitors of COVID-19 with repurposing approach via molecular docking. Network Modeling Analysis in Health Informatics and Bioinformatics, 11. pp. 1-11. ISSN 2192-6662

This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/106739/

This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher’s version. Please see the URL above for details on accessing the published version.

Copyright and reuse:
Sussex Research Online is a digital repository of the research output of the University.

Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available.

Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

http://sro.sussex.ac.uk
Screening of potential inhibitors of covid-19 with repurposing approach via molecular docking

Negin Alizadehmohajer¹, Abtin Behmardi², Simin Najafgholian³, Shabnam Moradi⁴, Forogh Mohammadi⁵, Reza Nedaeinia⁶, Shaghayegh Haghjooy Javanmard⁷, Ehsan Sohrabi⁸, Rasoul Salehi⁶,9, Gordon A. Ferns¹⁰, Asieh Emami Nejad¹¹, Mostafa Manian¹,12#

¹Department of Medical Laboratory Science, Faculty of Medicine, Kermanshah Branch, Islamic Azad University, Kermanshah, Iran.

²Cellular and Molecular Research Center, Research Institute for Prevention of Non-Communicable, Qazvin University of Medical Sciences, Qazvin, Iran.

³Department of Emergency Medicine, School of Medicine, Arak University of Medical Sciences, Arak, Iran.

⁴Department of Basic Sciences, School of Veterinary Medicine, Shiraz University, Shiraz, Iran.

⁵Department of Veterinary, Agriculture Faculty, Kermanshah Branch, Islamic Azad University, Kermanshah, Iran.

⁶Pediatric Inherited Diseases Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran.

⁷Applied Physiology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

⁸Department of Medical Genetics and Molecular Biology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.

⁹Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

¹⁰Brighton and Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN1 9PH, UK.

¹¹Department of Biology, Payame Noor University (PNU), P.O.Box 19395-3697, Tehran, Iran.

¹²Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Abstract

SARS-CoV-2 (COVID-19) is the causative organism or a pandemic disease with a high rate of infectivity and mortality. In this study, we aimed to assess the affinity between several available small-molecule and proteins, including Abl kinase inhibitors, Janus kinase inhibitor, Dipeptidyl peptidase 4 inhibitors, RNA-dependent RNA polymerase inhibitors, and Papin-like Protease inhibitors, using binding simulation, to test whether they may be effective in inhibiting COVID-19 infection through several mechanisms. The efficiency of inhibitors was evaluated based on docking scores using Auto Dock Vina software. Strong ligand-protein interactions were predicted among some of these drugs, that included: Imatinib, Remdesivir, and Telaprevir, and this may render these compounds promising candidates. Some candidate drugs might be efficient in disease control as potential inhibitors or lead compounds against the SARS-CoV-2. It is also worth highlighting the powerful immunomodulatory role of other drugs, such as Abivertinib that inhibits pro-inflammatory cytokine production associated with cytokine release syndrome (CRS) and the progression of COVID-19 infection. The potential role of other Abl kinase inhibitors, including Imatinib in reducing SARS-CoV and MERS-CoV viral titers, immune regulatory function and the development of acute respiratory distress syndrome (ARDS), indicate that this drug may be useful for COVID-19, as the SARS-CoV-2 genome is similar to SARS-CoV.

Keywords: COVID-19; Abl kinase inhibitors; Janus kinase inhibitor; Dipeptidyl peptidase 4 inhibitors; RNA-dependent RNA polymerase inhibitors, Papin-like Protease inhibitors.
1 Introduction

Coronaviruses are enveloped RNA viruses that include those causing severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) (1). SARS-CoV-2 is a newly emergent coronavirus that causes a respiratory illness and that has resulted in a global pandemic, having been first identified in Wuhan, China, in December 2019 (2, 3). COVID-19 has two categories of proteins; structural proteins that include: Spike (S) that characterize all coronaviruses, Nucleocapsid (N), Matrix (M), and Envelope (E); and non-structural proteins, that include: proteases (nsp3 and nsp5) and RdRp (nsp12) (1, 4). An essential step for replication of the enveloped viruses such as coronaviruses, is their entry into the host cells by fusing with cell membranes(5). The virus attaches and enters the host cells in the respiratory tract using the spike protein (4). It has also been shown that SARS-CoV-2 can infect T cells through a receptor-dependent, S protein-mediated membrane fusion (6). COVID-19 infection may be associated with lymphopenia and occasionally the release of very high levels of inflammatory cytokines that has been described as a “cytokine storm.” The latter has a major role in the development of inflammation-induced lung injury, that can lead to acute respiratory distress syndrome (ARDS), respiratory failure, and death (5, 7). Symptoms of COVID-19 include: dry cough, fever, breathing difficulties, headache, pneumonia (8), new loss of taste or smell, nausea or vomiting and diarrhea (9). An increased total neutrophil count and decreased total lymphocytes are related to disease severity and risk of mortality (10). There is currently no specific medication for COVID-19, so neutralizing monoclonal antibody-based therapeutics and small-molecules are being evaluated to treat COVID-19 (11). There are three key drug targeting strategies for SARS-CoV-2:

1. Blocking the entry of the virus into the host cells;
2. Host's undirected inflammatory response reduction;

3. Block replication within the host (12, 13).

Moreover, there are many factors that might contribute to viral infection through different mechanisms of action directly or indirectly, including Abl kinase, Janus kinase, Dipeptidyl peptidase 4, RNA-dependent RNA polymerase, viral main protease and Papin-like Protease, which will be discussed further. Repurposing FDA-approved drugs creates opportunities to develop new treatments for COVID-19, especially for patients who are suffering from severe disease; for example, there is the possibility that some drugs such as Imatinib can be repurposed (14). Other drugs are being evaluated in clinical trials, such as Abelson (Abl) kinase inhibitors (Imatinib), anti-malarials, RNA-dependent RNA polymerase (RdRP) inhibitors, and Papin-like Protease Inhibitors. The ClinicalTrials.gov Web site describes the candidate drugs currently being tested for COVID-19 prevention and/or treatment (Table 1). In silico evaluation of the possible viral inhibitory effectiveness of small molecules can be assessed by ligand-binding simulations. Therefore, the aim of this study was to evaluate the efficiency of candidate drugs and binding affinity with structural component of SARS-CoV-2, particularly in the contest of small-molecule inhibitors; Abl kinase inhibitors (Imatinib), Janus kinase inhibitor, Dipeptidyl peptidase 4 inhibitors, RdRP inhibitors, and Papin-like Protease inhibitors using in-silico simulations by auto dock vina software.

2 Methods

2.1 Protein preparation
For molecular docking, SARS-CoV-2 spike protein (PDB: 6XR8), SARS-CoV spike protein (PDB: 5X58), SARS-CoV-2 main protease (PDB: 6LU7), RNA-dependent RNA polymerases (RdRps) (PDB: 6M71), and papain-like protease (PLpro) (PDB: 6W9C) were chosen to be the target proteins which were obtained from the RCSB (http://www.rscb.org) Protein Data Bank in PDB format. Due to the high number of reported structures, in the present study, we used the structures, which had been previously studied in similar bioinformatics studies.

2.2 Ligands preparation

Based on literature reviews, we tested 3D structures of the drugs, including: Imatinib (Abl kinase inhibitor), Ruxolitinib and Baricitinib (JAK inhibitors), Sitagliptin (Dipeptidyl peptidase 4 inhibitors), Remdesivir, Ivermectin, Galidesivir, Ribavirin, Favipiravir (RdRps inhibitors), Telaprevir, Boceprevir, Grazoprevir (protease inhibitors) using Drug bank (https://www.drugbank.ca/) in Structure-data file (PDB) format. They also were converted into (PDBQT) by AutoDock Tools software. The PDBQT format is similar to PDB. However, it includes partial charges that are required for docking.

2.3 Docking analysis

To simulate protein and ligands binding affinity, molecular docking softwares (MVD) including AutoDock Tools (version 1.5.6) (http://autodock.scripps.edu) and AutoDock Vina (http://autodock.scripps.edu) were used (15, 16). After that, the downloaded proteins were inserted to the work place to be prepared. First, the water molecules were deleted and then, polar Hydrogen and Kollman charges were added by the software tools. Then, Autogrid determined the native ligand position on the binding site by arranging the grid coordinates (X, Y, and Z). After the preparations, the bioactive conformations were simulated by AutoDock Vina. The exhaustiveness
parameter that controls the extent of the search was chosen as 8, and 9 models were generated for each ligand. According to the received results, lower energy scores demonstrate the best protein-ligand interactions. Models with binding energy lower than 6 -kcal/mol can be considered. So, the lowest binding energy value of 10 -kcal/mol as a threshold to define a physical drug–target interaction was used. Different poses of the ligands affect the estimation of the docking score, so the most active forms were used in order to obtain an accurate estimation. RMSD values of 3 or more indicate that no docking has occurred. Only one docking positions with the root-mean-square deviations of atomic positions (RMSD=0) are highly valid and reported. The interactions of amino acids and ligands were also examined by using Discovery Studio 4.5.

2.4 Clinical Trials

Clinical Trials data were downloaded from clinicaltrials.gov on 4th April 2020. Small molecule drugs used to prevent or treat COVID-19 were selected in interventional category (Table 1).

3 Results and discussion

In the present study, based on the importance of inhibition in reducing or stopping the activity of COVID19- ligand with the ability to inhibit the virus in the drug database has been used. For this purpose, and considering the importance of identifying ligand-receptor interactions, the effectiveness of each of these ligands on the related proteins has been evaluated during the molecular docking simulation process.

3.1 Abl kinase inhibitors
Abl kinases are non-receptor tyrosine kinases that are involved in various cellular processes, especially as mediators of viral infection and/or may be involved in T-cell signaling (17). Imatinib is an Abl kinase inhibitor used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL). This small-molecule inhibitor works by inhibiting Bcr-Abl tyrosine-kinase (18). It has been shown, from previous studies, that an Abelson (Abl) kinase inhibitor, Imatinib, reduces SARS-CoV and MERS-CoV viral titers. In the same study, they also investigated the bronchitis virus (IBV) to study the function of Abl kinase activity during coronavirus infection and found that Imatinib and two different Abl kinase inhibitors, GNF2 and GNF5, reduced IBV titers by blocking virus infection (2). Previously, Imatinib was shown to block the entry of SARS-CoV or MERS-CoV S protein (2). SARS-CoV-2 is highly homologous to SARS-CoV, so studying the effects of Abl kinase inhibitors on IBV, SARS-CoV and MERS-CoV may be useful in identifying the host cell pathways required for COVID-19 infection. It may also provide insights into potential strategies for the treatment of COVID-19 especially by using Imatinib. Virus–cell and cell–cell fusion induced by the coronavirus S protein has a very similar mechanism. Abl kinase activity plays a role in cytoskeletal rearrangement, regulating endothelial barrier, and junctional dynamics, and hence Abl kinase inhibitors might also be capable of interacting by interfering with the actin dynamics needed for virus–cell and cell–cell fusion in SARA-CoV-2. Furthermore, studies have indicated that Abl kinase regulates inflammatory signaling, NFκB signaling, and oxidant-induced epithelial cells injury caused by infection and ARDS which can be followed by COVID-19 (2, 19). In epithelial cell injury H₂O₂ release leads to C-Abl activation and nuclear translocation. C-Abl inhibition by Imatinib increases the expression of antioxidant proteins such as catalase and glutathione peroxidase, which have been reduced due to oxidative stress. Therefore, treatment with Imatinib during ARDS may prevent
the death of lung cells (19). Coleman et al., investigated the Abl kinase inhibitors, including Imatinib, in SARS-CoV and MERS-CoV in vitro. In the early stages of infection, after internalization and endosomal trafficking, the anti-CoV activity of Imatinib is affected by inhibiting virion fusion in the endosomal membrane. Imatinib inhibits a step-in virion replication before the genomic production of RNA. They also investigated the role of Abl2 in the replication of SARS-CoV and MERS-CoV. To knock down the Abl2 protein levels, siRNA was used. They demonstrated that Abl2 expression is essential for a productive viral replication and can be blocked by Imatinib (20). Imatinib and its methane sulfonate derivative can be used in treating viral liver diseases, in particular viral hepatitis by inhibiting replication, transmission, or both, of hepatitis viruses or of other RNA viruses including respiratory syncytial virus, herpes virus, influenza virus, poxvirus, para influenza virus, rhinovirus, yellow fever virus, West Nile virus, and encephalitis virus in order to maintain or decrease RNA viral load. Although it is not meant to be limited to any particular mechanism of action or bound by definition, it is suspected that Imatinib's antiviral properties may be partly due to its ability to inhibit viral replication and transmission. Cellular signal transduction pathways are known to play an important role in viral infection, and cellular phosphorylation events during viral infection so they are required to effectively replicate and proliferate the virus. Several cellular signaling pathways, related to viral replication, have been investigated. Tyrosine kinase inhibitors can be used, for example, epidermal receptor growth factor (EGFR) inhibitors such as monoclonal antibodies and small-molecule inhibitors. EGFR inhibitors including monoclonal antibodies, such as IMC-C225 (Cetuximab), Trastuzumab (Herceptin), and others (ABX-EGF, EMD 72000), and tyrosine-kinase inhibitors, such as OSI-774 (Erlotinib, Tarceva), ZD1839 (Gefitinib, Iressa), and others (GW2016, CI-1033), can be used in combination therapy with Imatinib. Monoclonal antibodies can block extracellular ligand binding, but at the intracellular
portion of the receptor, the small-molecule inhibitors may exert their effects to prevent tyrosine kinase phosphorylation and the activation of signal transduction pathways (21). Consequently, combination therapy may be useful in COVID-19 treatment, similar to other RNA viruses. According to the Hubei Anti-Cancer Association Chronic Myeloid Leukemia Standardized Management Collaboration Group research on 299 CML patients who responded optimally to anti-CML therapy using Imatinib and other tyrosine kinase inhibitors, 0.3% of patients were infected by SARS-CoV-2 and among those who failed to respond to CML treatment, 2% of patients were diagnosed with COVID-19. Therefore, patients who failed to receive an appropriate response to anti-CML therapy medications were more likely to get infected by SARS-CoV-2. Although more detailed clinical data and studies on the prevalence of COVID-19 in patients with CML is required, this idea may be consistent with several possibilities (22). For instance, it has been shown that the total number of natural killer (NK) cells and Regulatory T cells was decreased markedly in patients with CML as well as COVID-19 infection (23, 24) while tyrosine kinase inhibitors are able to regulate the immune system by increasing the number of natural killer cells (NK) and Regulatory T cells (22). In order to assess the potential effectiveness of Imatinib on COVID-19, by using molecular docking, we investigated the affinity and efficiency of Imatinib and possible intermediary proteins: Spike protein and RNA-dependent RNA polymerases (RdRps). According to the NCBI database and using the Basic Local Alignment Search Tool (BLAST), we found that SARS-CoV-2 spike protein (PDB: 6XR8) and SARS-CoV spike protein (PDB: 5X58) Query Cover is 76.16% with a GMQE of 0.80, which indicates that it is reasonable to consider these proteins similar. The docking results are shown in Table 2; low energy indicates the optimum protein-ligand complexes. Accordingly, docking scores for SARS-CoV-2 and SARS CoV were -9.6 and -10 kcal/mol respectively which are low enough to show the appropriate protein-ligand
complexes. Docking interactions of Imatinib based on docking studies are shown in Figure 1. Furthermore, the type of interaction with the number of active site amino acids is also considered effective. In terms of interactions, the presence of hydrogen bond interactions can be very important as they have critical contributions to the binding structures and binding free energies, although the van der Waals and Pi-interactions contributed to the stabilization of the binding structures. If these interactions take place in the active position of proteins, it will be much better and more desirable. The interaction types and amino acids involved in the inhibition of proteins are shown in Table 6.

Binding interactions of Imatinib and SARS-CoV-2 spike protein shows that Imatinib interacts by forming hydrogen bonds with residue SER B: 50 and SER B: 967. A pi-sigma interaction is also visible between the drug and amino acid THR B: 302 and Pi-Alkyl interactions with LEU C: 754 and CYS C: 760. The large number of Pi-sigma interactions which involves charge transfer and helps in intercalating the drug in the binding site of the receptor. Pi-alkyl bond also improves the hydrophobic interactions of the ligand in the binding pocket of the receptor. With regards to the van der Waals interactions, it should be mentioned that there are thirteen amino acids contributing to the ligand binding, including: LYS B: 304, HIS B: 49, ASN C: 764, CYS C: 738, ASP C: 737, VAL C: 736, SER C: 735, THR B: 315, GLN B: 314, SER B: 316, ARG B: 319, THR B: 274 and GLY C: 757. Imatinib inhibits SARS-CoV-2 with an IC50 of 130nM. But, although imatinib binds to the receptor-binding domain (RBD) of SARS-CoV-2 spike protein, it does not inhibit the spike RBD: ACE2 interaction, suggesting a Bcr-Abl kinase-mediated fusion inhibition mechanism is responsible for the inhibitory action (25). Abivertinib is another small molecule tyrosine kinase inhibitor (TKI) that is used in lung cancer treatment, targeting both mutant forms of the epidermal growth factor receptor (EGFR) and
Bruton's tyrosine kinase (BTK). Abivertinib binds to the BTK receptor which results in receptor phosphorylation prevention. It also plays a powerful immunomodulatory role in vitro by inhibiting pro-inflammatory cytokine production that are associated with cytokine release syndrome (CRS) or cytokine storm and progression of COVID-19 infection such as IL-1beta, IL-6 and TNF-alpha in patients with acute respiratory distress syndrome (ARDS). It is worth noting that FDA clears Abivertinib for Phase 2 safety and efficacy study in hospitalized patients with moderate to severe COVID-19 (http://www.aceatherapeutics.com). This strongly indicates that the Abl kinase signaling pathway is a promising area to study for the development of antiviral therapies.

3.2 Janus kinase inhibitor (JAK inhibitor)

Janus kinase inhibitors are being used in the treatment of cancer and inflammatory diseases by inhibiting the activity of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), by interfering with the JAK-STAT signaling pathway (26). Ruxolitinib is one of those inhibitors with an anti-inflammatory effect related to the inhibition of the release of cytokines. This drug is used for the treatment of myelofibrosis and polycythemia vera (PCV) (27). Ruxolitinib has been approved in Covid-19 patients with respiratory failure with no invasive assisted ventilation required (28). Improvement in chest computed tomography and faster recovery from lymphopenia were seen in patients as well (29). Another JAK inhibitor is Baricitinib used for rheumatoid arthritis. A randomized phase 2 trial for this drug has been licensed to the usual treatment of pneumonia in COVID-19 patients (28). Transcription by interferon-activated JAK – STAT signaling pathway (mainly mediated by JAK1 and JAK2) contributes to the upregulation of several interferon-controlled genes which destroy viruses in infected cells rapidly. Many viruses have formed strategies to combat interferon effects by blocking their signaling pathways,
and viral-encoded factors that antagonize the JAK – STAT pathway are important virulence determinants. So, the blocking of the JAK – STAT signal by Baricitinib results in interferon-mediated antiviral response inhibition that has an impact on SARS-CoV-2 infection progression (30). According to another cohort study, Baricitinib in combination with Remdesivir and Hydroxychloroquine showed clinical improvement in patients (31). Moreover, docking results between SARS-CoV-2 main protease and our two JAK inhibitors (Ruxolitinib and Baricitinib) were -6.2 and -6.1 kcal/mol respectively (Table 3).

3.3 Dipeptidyl peptidase 4 inhibitors (DPP4i)

Besides the main viral entrance port, angiotensin converting enzyme 2 (ACE2), dipeptidyl peptidase 4 (DPP4) can be investigated as well. DPP4 is a type II transmembrane glycoprotein with its major role in glucose and insulin metabolism which is expressed in many tissues, such as the immune cells. Also, it plays a significant role in immune regulation by activating Tcells, modulating NF-jB pathway, and the expression of CD86. Dipeptidyl peptidase 4 inhibitors mainly sitagliptin can be used to treat diabetes mellitus type 2. Moreover, it was identified as a functional receptor for the MERS-CoV spike protein and although SARS-CoV-2 spike protein does not necessarily need DPP4. In spite of Sitagliptin and SARS-CoV-2 spike protein docking result with the score of -6.0 kcal/mol and the possibility that it does not alter ACE2, the potential anti-inflammatory involvement of DPP4 inhibitors raises concerns about DPP4 modulation that might decrease the cytokine-mediated acute respiratory complications of COVID-19 infection (28, 32) (Table 3).

3.4 RNA-dependent RNA polymerase Inhibitors

RNA-dependent RNA polymerase (RdRP) is an enzyme that catalyzes the replication of RNA from an RNA template which is encoded in the genomes of all
RNA viruses (33) including SARS-CoV-2. There are some drugs that are considered to be nucleotide analog inhibitors of RdRps. Remdesivir (RDV) is one of those investigational drugs that have a wide variety of antiviral activities against RNA viruses including coronaviruses (34). Remdesivir suppresses viral replication and it was initially tested in clinical trials to prevent the 2014 Ebola outbreak. Later investigations indicated Remdesivir's ability to inhibit replication of coronavirus, including SARS-CoV-2 as well (35). In another cohort study, medical progress was observed in 68% of patients taken to the hospital with severe COVID-19 treated with Remdesivir (36). Ivermectin is another medication that we investigated via molecular docking. It is used to treat many types of parasite infestations, but recently the antiviral effects against several SARS-CoV-2 have been identified. Ivermectin may inhibit the replication of SARS-CoV-2 in monkey with an IC50 of 2.2 - 2.8 µM, which makes it a possible candidate for drug repurposing research. Also, it is an in vitro inhibitor of SARS-CoV-2 replication via Importin α/β1 function (37, 38). According to our docking result, it showed high affinity value of -8.8 kcal/mol with RdRP. In Japan, Favipiravir, an antiviral drug that targets the influenza viral RNA-dependent RNA polymerase, has been used against SARS-CoV-2 (39). Ribavirin and Galidesivir (4) are other recommended drugs that we studied using auto dock vina. Accordingly, Remdesivir (Figure 1) has the best binding capability with the score of -9.0 kcal/mol. From our docking studies, with the better binding energy compounds, the identified active residues were Lys47, Ser784, Ser709, Tyr129, His133 and Thr141. The major interaction between Remdesivir and RdRP is characterized by hydrogen bonding between the oxygen with TYR A: 129. A Pi-Cation interaction of aromatic ring and LYS A: 780 and an Alkyl interaction with ALA A: 706 have been observed. The docked result of the shown in Figure 1 indicates the drug has eight hydrogen bond interactions with six amino acids shown in Table 6. Other important
interactions such as alkyl, Pi-cation interactions were also reported Table 6. Remdesivir high affinity has also been correlated with the existence of Van der waal forces formed on the amide substituents backbone with the respective amino acids GLY A: 774, ASP A: 135, ALA A: 46. THR A: 710, LYS A: 714, GLN A: 773, ASN A: 705 AND SER A: 784, which established a strong cohesive environment, thus stabilizing the formed complex. It exhibits effective in vitro activity against SARS-CoV-2 with an EC$_{50}$ at 48h of 0.77µM in Vero E6 cells (6). On the other hand, Favipiravir had the least affinity to RdRps despite the recorded efficiency based on clinical trials (Table 4).

3.5 Papain-like Protease Inhibitors

Papain-like Protease (PLpro) is characterized in different coronaviruses, including SARS and MERS (40). The genome of SARS-CoV-2 encodes for different proteins including PLpro(41). The SARS-CoV PLpro and SARS-CoV-2 PLpro protein sequences are similar, so protease inhibitors that have shown efficacy against SARS-CoV might be similarly effective against SARS-CoV-2. Papain-like protease (PLpro) has a crucial role in the viral life-cycle (42, 43). Targeting PLpro with antiviral drugs may result in viral replication blockage and the deregulation of signaling cascades in infected cells inhibition (44). Consequently, anti-HCV drugs (Telaprevir, Grazoprevir, and Boceprevir) that bind to the SARS-CoV-2 PLpro active site (contained residues Asp164, Val165, Arg166, Glu167, Met 208, Ala246, Pro247, Pro248, Tyr 264, Gly266, Asn267, Tyr 268, Gln269, Cys217, Gly271, Tyr273, Thr301 and Asp302), may therefore oppose viral replication (40, 45). Similarly, our study showed that Telaprevir (Figure 1), Grazoprevir, and Boceprevir (HCV protease inhibitor) may be effective in binding to SARS-CoV-2 papain-like protease (PLpro) active sites to prevent viral replication (Table 5)(46). Regarding the lowest binding energy, the best ligand was found to be Telaprevir with a score
of -9.9 kcal/mol. The results of docking analysis (Table 6) showed that Telaprevir forms hydrogen bonds with the 6W9C amino acids LYS B:92, HIS B:89 and THR A:74. Also there can be seen that the ligand interacts with LYS B: 92 via Pi-cation and TYR A: 171 and ILE B: 44 via Pi-Alkyl interactions.

4 Conclusions

Our results show that the treatment of COVID-19 may potentially be addressed by repurposing existing, approved pharmaceutical drugs. In this virtual drug repurposing study based on docking analysis, using an established database for protein and ligand structures, we obtained the predicted binding scores of several drugs. This will be important in evaluating the findings of continuing clinical trials testing small molecule drugs for efficacy against SARS-CoV-2 and the drugs different mechanisms of action. Imatinib plays roles in cytoskeletal rearrangement, inflammatory signaling, NK and Regulatory T cell modulation, and oxidant-induced epithelial cell injury followed by infection and ARDS which has been diagnosed among COVID-19 patients. Another TKI, Abivertinib, has an immunomodulatory function in patients with ARDS. Also, Remdesivir, and Telaprevir have the most efficiency with their docked proteins in-silico as well.

Abbreviations

ARDS: Acute respiratory distress syndrome; SARS-CoV: Severe acute respiratory syndrome coronavirus; MERS-CoV; Middle East respiratory syndrome coronavirus; ACE: Angiotensin-converting enzyme; PDB: Protein Data Bank; PDBQT: Protein Data Bank, Partial Charge (Q), & Atom Type (T); MVD: Molecular docking software; CML: Chronic myelogenous leukemia; ALL: Acute lymphocytic leukemia; TKI: tyrosine kinase inhibitor; EGFR: epidermal growth factor receptor; BTK: Bruton's tyrosine kinase; CRS: cytokine release syndrome; JAK inhibitor:
Janus kinase inhibitor; ACE2: Angiotensin converting enzyme 2; AT2R: Angiotensin II receptor; DPP4i: Dipeptidyl peptidase 4 inhibitors; RdRP: RNA-dependent RNA polymerase; RDV: Remdesivir.

Acknowledgements
Not applicable.

Funding
Not applicable.

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Declaration of Competing Interest
The authors declare that they have no competing interests.

Availability of data and material
The data supporting the findings of this study are available within the article
References

1. Divya M, Vijayakumar S, Chen J, Vaseeharan B, Durán-Lara EF. South Indian medicinal plants can combat deadly viruses along with COVID-19? - A review. Microbial pathogenesis. 2020;104277.
2. Sisk JM, Frieman MB, Machamer CE. Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors. The Journal of general virology. 2018;99(5):619.
3. Organization WH. Coronavirus disease 2019 (COVID-19): situation report, 45. 2020.
4. Ibrahim IM, Abdelmalek DH, Elshahat ME, Elfiky AA. COVID-19 spike-host cell receptor GRP78 binding site prediction. Journal of Infection. 2020;80(5):554-62.
5. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pacific J allergy Immunol. 2020;10.
6. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research. 2020;30(3):269-71.
7. Chen C, Zhang X, Ju Z, He W. Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies. Zhonghua shaoshang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns. 2020;36:E005.
8. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3.
9. DiBiasi RL, Song X, Delaney M, Bell M, Smith K, Pershad J, et al. Severe COVID-19 in children and young adults in the Washington, DC metropolitan region. The Journal of Pediatrics. 2020.
10. Sun M, Yang J, Sun Y, Su G. Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases. 2020;43:E014.
11. Choudhary S, Malik YS, Tomar S, Tomar S. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using in Silico Structure-Based Virtual Screening Approach. ChemRxiv; 2020.
12. Jakovac H. COVID-19: is the ACE2 just a foe? American Journal of Physiology-Lung Cellular and Molecular Physiology. 2020;318(5):L1025-L6.
13. Quartuccio L, Semerano L, Benucci M, Boissier M-C, De Vita S. Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome. Joint Bone Spine. 2020;87(3):191.
14. Shaw TD, McCauley DF, O’Kane CM. Emerging drugs for treating the acute respiratory distress syndrome. Expert Opinion on Emerging Drugs. 2019;24(1):29-41.
15. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of computational chemistry. 2010;31(2):455-61.
16. Tools A. 1.5. 6 (ADT)/MGL Tools 1.5. 6, The Scripps Research Institute, CA, USA, 2012. 2016.
17. Khatri A, Wang J, Pendergast AM. Multifunctional Abl kinases in health and disease. Journal of Cell Science. 2016;129(1):9.
18. Kerkelä R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nature medicine. 2006;12(8):908-16.
19. Rizzo AN, Aman J, van Nieuw Amerongen GP, Dudek SM. Targeting Abl kinases to regulate vascular leak during sepsis and acute respiratory distress syndrome. Arteriosclerosis, thrombosis, and vascular biology. 2015;35(5):1071-9.
20. Coleman CM, Sisk JM, Mingo RM, Nelson EA, White JM, Frieman MB. Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and middle east respiratory syndrome coronavirus fusion. Journal of virology. 2016;90(19):8924-33.
21. Riviere P, Riviere M, Reader S. Use of imatinib to treat liver disorders and viral infections. Google Patents; 2012.
22. Wang D-Y, Guo J-M, Yang Z-Z, You Y, Chen Z, Chen S-M, et al. The First Report of the Prevalence of COVID-19 in Chronic Myelogenous Leukemia Patients in the Core Epidemic Area of China: A Multicentre, Cross-Sectional Survey. 2020.
23. Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cellular & Molecular Immunology. 2020.
24. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clinical Infectious Diseases. 2020.
25. Mulgaonkar N, Wang H, Mallawarachchi S, Fernando S, Martina B, Ruzek D. Bcr-Abl tyrosine kinase inhibitor imatinib as a potential drug for COVID-19. bioRxiv. 2020:2020.06.18.158196.
26. Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O'Shea JJ. Therapeutic targeting of Janus kinases. Immunological reviews. 2008;223(1):132-42.
27. Mesa RA, Yasothan U, Kirkpatrick P. Ruxolitinib. Nature Reviews Drug Discovery. 2012;11(2):103-4.
28. Li Lorenzo G, Di Trolio R, Kozlakidis Z, Busto G, Ingenito C, Buonerba L, et al. COVID 19 therapies and anti-cancer drugs: A systematic review of recent literature. Critical Reviews in Oncology/Hematology. 2020:102991.
29. Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology. 2020:146(1):137-46.e3.
30. Favalli EG, Biggioggero M, Maioli G, Caporali R. Baricitinib for COVID-19: a suitable treatment? The Lancet Infectious Diseases. 2020.
31. Titanji BK, Farley MM, Mehta A, Connor-Schuler R, Moanna A, Cribbs SK, et al. Use of Baricitinib in Patients with Moderate and Severe COVID-19. Clinical Infectious Diseases. 2020.
32. Pal R, Bhadada SK. Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? Diabetes research and clinical practice. 2020;163.
33. Koonin EV, Gorbalenya AE, Chumakov KM. Tentative identification of RNA-dependent RNA polymerases of dsRNA viruses and their relationship to positive strand RNA viral polymerases. FEBS Letters. 1989;252(1-2):42-6.
34. Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Gotte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. Journal of Biological Chemistry. 2020;jbc.AC120.013056.
35. Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, et al. Remdesivir: A Review of Its Discovery and Development Leading to Human Clinical Trials for Treatment of COVID-19. 2020.
36. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. New England Journal of Medicine. 2020.
37. Caly L, Drice JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research. 2020;178:104787.
38. YAVUZ S, Ünal S. Antiviral treatment of COVID-19. Turkish Journal of Medical Sciences. 2020;50(S1-1):611-9.
39. Chen C, Huang J, Cheng Z, Wu J, Chen S, Zhang Y, et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv. 2020:2020.03.17.20037432.
40. Elfyky A, Ibrahim NS. Anti-SARS and anti-HCV drugs repurposing against the Papain-like protease of the newly emerged coronavirus (2019-nCoV). Research Square preprint. 2020.
41. Durdagi S, Aksoydan B, Dogan B, Sahin K, Shahraki A. Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of COVID-19 Main Protease: A Virtual Drug Repurposing Study. 2020.
42. Arya R, Das A, Prashar V, Kumar M. Potential inhibitors against papain-like protease of novel coronavirus (SARS-CoV-2) from FDA approved drugs. 2020.
43. Talluri S. Virtual High Throughput Screening Based Prediction of Potential Drugs for COVID-19. 2020.
44. Claudio C, Juan Di F. In silico Drug Repurposing for COVID-19: Targeting SARS-CoV-2 Proteins through Docking and Quantum Mechanical Scoring. 2020.
45. Arya R, Das A, Prashar V, Kumar M. Potential Inhibitors Against Papain-like Protease of Novel Coronavirus (COVID-19) from FDA Approved Drugs. 2020.
46. Elfiky AA, Ibrahim NS. Anti-SARS and Anti-HCV Drugs Repurposing Against the Papain-like Protease of the Newly Emerged Coronavirus (2019-nCoV). 2020.

Figure 1

Figures legend
**Figure 1.** Visualization of docked poses of top 3 drug candidates with their protein target

a. Binding interactions of Imatinib with active site residues of SARS-CoV-2 spike protein.

a’: 3D view of Imatinib with surrounding amino acids of 6XR8.

b. Binding interactions of Remdesivir with active site residues of RdRP.

b’: 3D view of Remdesivir with surrounding amino acids of 6M71.

c. Binding interactions of Telaprevir with active site residues of PLpro.

c’: 3D view of Telaprevir with surrounding amino acids of 6W9C.

**Table 1.** Clinical trials related to the coronavirus disease 2019-nCoV and candidate drugs

| ClinicalTrials.gov identifier | Drug class | Drug name | Estimated enrollment | aim | Primary purpose |
|------------------------------|------------|-----------|----------------------|-----|-----------------|
| NCT04357613                 | Abl Kinase Inhibitor | Imatinib | 99 participants | Test the value of Imatinib as an early treatment of COVID-19 | Treatment |
| NCT04330300                 | ACE Inhibitor, Angiotensin Receptor Blocker | Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Perindopril, Quinapril, Ramipril, Trandolapril | 2414 participants | CORONA virus Angiotensin Converting Enzyme Inhibitors, Angiotensin Receptor Blockers Investigation | Prevention |
| NCT04280705                 | RdRps Inhibitor | Remdesivir | 1062 participants | Evaluate the efficacy and safety of Remdesivir (Phase 3) | Treatment |
| NCT04276688                 | RdRps Inhibitor, 3CLpro Inhibitor | Ribavirin, Lopinavir, Ritonavir | 127 participants | Investigate a combination of Lopinavir, Ritonavir, | Treatment |
| NCT04310228         | RdRps Inhibitor, Interleukin-6 (IL-6) Blockers | Favipiravir, Tocilizumab | 150 participants | Evaluate the efficacy and safety of Favipiravir combined with Tocilizumab | Treatment |
|---------------------|-----------------------------------------------|--------------------------|------------------|--------------------------------------------------------------------------|------------|
| NCT04307693         | 3CL Protease Inhibitor                        | Lopinavir, Ritonavir     | 65 participants  | Investigate Lopinavir, Ritonavir in Patients with mild Coronavirus disease | Treatment |
| NCT04440007         | EGFR Tyrosine Kinase Inhibitor and BTK Inhibitor | Abivertinib             | 80 participants  | A phase 2 randomized study of the efficacy and safety of Abivertinib maleate in hospitalized patients with COVID-19 | Treatment |
| NCT04321993         | Janus Kinase Inhibitor                        | Baricitinib              | 800 participants | Treatment of moderate to severe Coronavirus disease in hospitalized patients | Treatment |
| NCT04365517         | Dipeptidyl Peptidase 4 Inhibitor              | Sitagliptin              | 170 participants | The effect of Sitagliptin treatment in COVID-19 positive diabetic patients | Treatment |
| NCT04377620         | Janus-Associated Kinase (JAK) Inhibitor       | Ruxolitinib              | 500 participants | Assess the efficacy and safety of Ruxolitinib in participants with COVID-19-associated ARDS | Treatment |
| NCT03891420         | Viral RNA Polymerase Inhibitor                | Galidesivir              | 132 participants | Evaluate the safety, pharmacokinetics, and anti-viral effects of Galidesivir | Treatment |

**Table 2.** The docking score of Imatinib to SARS-CoV-2 and SARS-CoV spike protein, SARS-CoV-2 RNA- dependent RNA polymerases (RdRps) (RMSD: 0.00)
| Drug name     | Drug bank ID | 2D structure | Protein target          | Drug use                                         | Binding affinity (total energy) |
|--------------|--------------|--------------|-------------------------|-------------------------------------------------|---------------------------------|
| Ruxolitinib  | DB08877      | ![Structure](image) | SARS-CoV-2 main protease | Treatment of intermediate or high-risk myelofibrosis | -6.2                            |
| baricitinib  | DB11817      | ![Structure](image) | SARS-CoV-2 main protease | Treatment of rheumatoid arthritis (RA)           | -6.1                            |
| Sitagliptin  | DB01261      | ![Structure](image) | SARS-CoV-2 spike protein | Treatment of diabetes mellitus type 2            | -6.0                            |

| Drug name | Drug bank ID | 2D structure | Protein target | CoV-2 spike protein | CoV spike protein | 2 RNA-dependent RNA polymerases (RdRps) |
|-----------|--------------|--------------|----------------|--------------------|-------------------|---------------------------------------|
| Imatinib  | DB00619      | ![Structure](image) | Anti-cancer     | -9.6               | -10               | -8.1                                  |

**Table 3.** The docking score of candidate inhibitors to SARS-CoV-2 main protease and SARS-CoV-2 spike protein. (RMSD: 0.00)
Table 4. The docking score of candidate inhibitors to SARS-CoV-2 RNA-dependent RNA polymerases (RdRps) (RMSD: 0.00)

| Drug name | Drug bank ID | 2D structure | Drug use   | Binding affinity (total energy) |
|-----------|--------------|--------------|------------|-------------------------------|
| Remdesivir| DB14761      | ![Remdesivir 2D structure](image) | Antiviral  | -9.0                          |
| Ivermectin| DB00602      | ![Ivermectin 2D structure](image) | anti-parasite | -8.8                         |
| Galidesivir| DB11676     | ![Galidesivir 2D structure](image) | Antiviral  | -6.9                          |
| Ribavirin | DB00811      | ![Ribavirin 2D structure](image) | Antiviral  | -6.3                          |
Table 5. The docking score of candidate HCV protease inhibitors to SARS-CoV-2 Papain-like protease (PLpro) (RMSD: 0.00)

| Drug name     | Drug bank ID | 2D structure | Drug use        | Binding affinity (total energy) |
|---------------|--------------|--------------|-----------------|--------------------------------|
| Telaprevir    | DB05521      | ![Telaprevir](image) | Anti-Hepatitis C | -9.9                           |
| Grazoprevir   | DB11575      | ![Grazoprevir](image) | Anti-Hepatitis C | -8.7                           |
| Boceprevir    | DB08873      | ![Boceprevir](image) | Anti-Hepatitis C | -7.8                           |
### Table 6. Interaction types and Amino acids involved in the Inhibition of PDB: 6XR8, PDB: 6M71 and PDB: 6W9C with the top three drug candidate.

| Ligand   | Protein      | Conventional Hydrogen Bond | Carbon bond | Pi-sigma and amide interaction | Alkyl Interaction | Pi-Cation interaction |
|----------|--------------|----------------------------|-------------|-------------------------------|-------------------|-----------------------|
| Imatinib | PDB: 6XR8    | SER B: 50                  | THR C: 761  | THR B: 302                    | CYS C: 760        | LEU C: 754            | -                     |
|          |              | SER B: 967                 |             |                               |                   |                       |                       |
| Remdesivir | PDB: 6M71   | ASN A: 781                 | SER A: 709  | -                             | ALA A: 706        | LYS A: 780            |
|          |              | HIS A: 133                 |             |                               |                   |                       |
|          |              | SER A: 709                 |             |                               |                   |                       |
|          |              | TYR A: 129                 |             |                               |                   |                       |
|          |              | LYS A: 47                  |             | ALA A: 706                    |                   |                       |
|          |              | ASP A: 711                 |             |                               |                   |                       |
| Telaprevir | PDB: 6W9C   | LYS B: 92                  | HIS B: 89   | -                             | ILE B: 44         | LYS B: 92             |
|          |              | THR A: 74                  |             |                               | TYR A: 171        |                       |

And PDB: 6W9C with the top three drug candidate.